Results for dinutuksimabom translation from Croatian to English

nisu prijavljeni slučajevi predoziranja dinutuksimabom.
no cases of dinutuximab overdose have been reported.

preporučuje se redovito praćenje funkcije jetre tijekom imunoterapije dinutuksimabom.
regular monitoring of liver function is recommended during dinutuximab immunotherapy.

analize odgovora efs i os po podskupinama su pokazale da bolesnici s minimalnom rezidualnom bolešću, hiperploidnom dnk i oni koji su primili pročišćenu koštanu srž možda nisu imali koristi od imunoterapije dinutuksimabom.
subgroup analyses of efs and os response indicated that patients with minimal residual disease, dna hyperploidy, and those having received a purged bone marrow may not have benefited from dinutuximab immunotherapy.

neklinička ispitivanja pokazuju da dinutuksimabom uzrokovana neurotoksičnost vjerojatno nastaje zbog izazivanja mehaničke alodinije koju može posredovati reaktivnost dinutuksimaba s antigenom gd2 smještenim na površini perifernih živčanih vlakana i/ili mijelina.
non-clinical studies demonstrate that dinutuximab-induced neurotoxicity is likely due to the induction of mechanical allodynia that may be mediated by reactivity of dinutuximab with gd2 antigen located on the surface of peripheral nerve fibres and/or myelin.

povećanje stanične citotoksičnosti ovisne o protutijelima u prisutnosti gm-csf-a i il-2 dalo je osnovu za kombiniranje ovih citokina s dinutuksimabom u kliničkim ispitivanjima.
augmentation of adcc in the presence of gm-csf and il-2 provided the rationale for combining these cytokines with dinutuximab in clinical studies.

tablica 4 : smjernice za prilagodbu doze za zbrinjavanje nuspojava nastalih tijekom liječenja dinutuksimabom u kombinaciji s gm-csf-om, il-2 i izotretinoinom
table 4: dose modification guidance for the management of treatment-emergent adverse reactions during administration of dinutuximab in combination with gm-csf, il-2 and isotretinoin.

dvogodišnje procjene preživljenja bez događaja su iznosile 66% među ispitanicima koji su primali imunoterapiju dinutuksimabom uz izotretinoin, u usporedbi s 48% u ispitanika koji su primali samo izotretinoin (log-rang test p = 0,033), premda ova razlika formalno nije bila statistički značajna prema unaprijed utvrđenom planu interim analiza.
the 2-year estimates of efs were 66 % among subjects receiving dinutuximab immunotherapy plus isotretinoin as compared with 48 % in subjects receiving isotretinoin alone (log-rank test p = 0.033) although this difference did not reach formal statistical significance according to the pre-specified plan for interim analyses.